Buprenorphine

Major

Buprenorphine Lorcaserin Explained An increased risk of serotonin syndrome Details Buprenorphine Lorlatinib Lorbrena Explained Reduced buprenorphine exposure and reduced efficacy of buprenorphine Details Buprenorphine Lormetazepam Explained An increased risk of CNS depression and respiratory depression Details Buprenorphine Loxapine Adasuve Explained An increased risk of respiratory and CNS depression and an increased risk of paralytic ileus Details Buprenorphine Lumacaftor Explained Reduced buprenorphine exposure and reduced efficacy of buprenorphine Details Buprenorphine Lumefantrine Explained An increased risk of QT interval prolongation Details Buprenorphine Lurasidone Latuda Increased risk of respiratory and CNS depression Details Buprenorphine Macimorelin Explained Increased risk of QT interval prolongation Details Buprenorphine Magnesium Oxybate Xywav Explained An increased risk of CNS depression and clinically significant respiratory depression, obtundation, hypotension, profound sedation... Details Buprenorphine Mavorixafor Xolremdi Explained An increased risk of QT interval prolongation and torsade de pointes Details Buprenorphine Meclizine Antivert Explained An increased risk of respiratory and CNS depression and an increased risk of paralytic ileus Details Buprenorphine Medazepam Explained An increased risk of CNS depression and respiratory depression Details Buprenorphine Mefloquine Lariam® An increased risk of QT interval prolongation Details Buprenorphine Melitracen Explained An increased risk of serotonin syndrome Details Buprenorphine Melperone Explained An increased risk of respiratory depression and CNS depression Details Buprenorphine Mepenzolate Explained An increased risk of paralytic ileus Details Buprenorphine Meperidine Demerol Explained Reduced analgesic effect or precipitation of withdrawal symptoms, and an increased risk of serotonin syndrome Details Buprenorphine Mephobarbital Explained An increased risk of respiratory depression and CNS depression Details Buprenorphine Meprobamate Explained An increased risk of respiratory depression and CNS depression Details Buprenorphine Meptazinol Explained Reduced analgesic effect or precipitation of withdrawal symptoms, and an increased risk of serotonin syndrome and respiratory depr... Details Buprenorphine Metaclazepam Explained An increased risk of CNS depression and respiratory depression Details Buprenorphine Metaxalone Skelaxin Explained Increased risk of serotonin syndrome, an increased risk of respiratory depression and an increased risk of CNS depression Details Buprenorphine Methadone Diskets Explained Reduced analgesic effect or precipitation of withdrawal symptoms, an increased risk of serotonin syndrome, an increased risk of re... Details Buprenorphine Methamphetamine Desoxyn Explained An increased risk of serotonin syndrome Details Buprenorphine Methdilazine Explained An increased risk of respiratory depression and CNS depression Details Buprenorphine Methocarbamol Atmeksi Explained Enhanced neuromuscular blocking action and an increased risk of respiratory depression and CNS depression Details Buprenorphine Methohexital Brevital Explained An increased risk of respiratory depression and CNS depression Details Buprenorphine Methotrimeprazine Explained An increased risk of QT interval prolongation and an increased risk of CNS and respiratory depression Details Buprenorphine Methyclothiazide Explained Reduced efficacy of diuretics Details Buprenorphine Methylene Blue Provayblue Explained An increased risk of CNS depression and an increased risk of serotonin syndrome or opioid toxicity Details Buprenorphine Metoclopramide Explained Increased risk of CNS depression Details Buprenorphine Metolazone Explained Reduced efficacy of diuretics Details Buprenorphine Metronidazole Flagyl An increased risk of QT interval prolongation Details Buprenorphine Midazolam Explained An increased risk of CNS depression and respiratory depression Details Buprenorphine Mifepristone Korlym Explained An increased risk of QT interval prolongation, increased buprenorphine exposure and an increased risk of buprenorphine-related adv... Details Buprenorphine Milnacipran Savella Explained An increased risk of serotonin syndrome Details Buprenorphine Milsaperidone Explained An increased risk of QT interval prolongation Details Buprenorphine Mirtazapine Mirataz Explained Increased risk of serotonin syndrome, an increased risk of QT interval prolongation and an increased risk of torsades de pointes Details Buprenorphine Mitotane Lysodren Explained Reduced buprenorphine exposure and reduced efficacy of buprenorphine Details Buprenorphine Mizolastine Explained An increased risk of QT interval prolongation Details